Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2014-12-04 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Appendix 3X - Initial Director's Interest Notice 4 pages 241.8KB
Regulatory Filings
2014-12-04 English
HPV Vaccine Heads to the Clinic 2 pages 302.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Admedus Limited dated 24 November 2014, discussing the progress of their HPV therapeutic vaccine into a Phase Ib clinical study. It highlights preclinical study results and future clinical plans. The content is a corporate announcement about a product development milestone rather than a financial report, regulatory filing, or shareholder meeting material. It does not contain financial statements, voting results, management changes, or legal proceedings. The document is relatively short (3898 characters) and serves as a news update on clinical progress. Therefore, it fits best under the category of a general regulatory announcement or corporate update. Given the available categories, the closest match is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2014-11-23 English
AGM - Presentation to Shareholders 18 pages 806.0KB
AGM Information Classification · 95% confidence The document is a presentation titled 'Admedus Limited 2014 Annual General Meeting' and includes an overview of the company, business highlights, strategy, sales, product development, and future plans. It is structured as a slide deck with disclaimers and forward-looking statements typical of investor or shareholder presentations. The content focuses on company performance over the past year and outlook for the next year, consistent with materials shared at an Annual General Meeting. There is no detailed financial statement or audit report included, nor is it a brief announcement or regulatory filing. The length (over 10,000 characters) and content indicate it is the actual presentation material rather than a short announcement. Therefore, the document best fits the category of AGM Information (AGM-R).
2014-11-13 English
Results of Annual General Meeting 2 pages 341.9KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement titled 'RESULTS OF 2014 ANNUAL GENERAL MEETING' and provides detailed voting results for resolutions passed at the AGM. It references the Corporations Act 2001 and Listing Rule 3.13.2, which govern disclosure of voting outcomes. The content is focused on the official results of shareholder votes at the AGM, including votes for adoption of remuneration report, re-election of directors, and approval of placements. The document is short (1905 characters) and is clearly an announcement of voting results rather than the AGM materials themselves or the full annual report. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2014-11-13 English
Admedus receives Originating Process 2 pages 298.4KB
Legal Proceedings Report Classification · 95% confidence The document is an ASX announcement dated 12 November 2014 regarding legal proceedings issued against Admedus Limited and its subsidiaries by minority shareholders in a subsidiary business. The content focuses on describing the nature of the legal dispute, the parties involved, and the company's response to the allegations. There are no financial statements, management discussion of financial results, or detailed report data. The document is a regulatory announcement informing shareholders and the market about ongoing legal proceedings, which fits the category of Legal Proceedings Report. The document length is 3433 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is Legal Proceedings Report (LTR).
2014-11-11 English
Change in substantial holding 4 pages 1.6MB
Regulatory Filings
2014-11-09 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.